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Available online 17 April 2018Background:Modulation of genetic variants on the effect of omega-3 fatty acid supplements on blood lipids is still
unclear.
Methods: In a double-blind randomized controlled trial, 150 patients with type 2 diabetes (T2D) were random-
ized into omega-3 fatty acid group (n = 56 for fish oil and 44 for flaxseed oil) and control group (n = 50) for
180 days. All patients were genotyped for genetic variants at CD36 (rs1527483), NOS3 (rs1799983) and PPARG
(rs1801282). Linear regression was used to examine the interaction between omega-3 fatty acid intervention
and CD36, NOS3 or PPARG variants for blood lipids.
Findings: Significant interactionwith omega-3 fatty acid supplementswas observed for CD36 on triglycerides (p-
interaction= 0.042) and PPAGR on low-density lipoprotein-cholesterol (p-interaction = 0.02). We also found a
significant interaction between change in erythrocyte phospholipid omega-3 fatty acid composition and NOS3
genotype on triglycerides (p-interaction = 0.042), total cholesterol (p-interaction = 0.013) and ratio of total
cholesterol to high-density lipoprotein cholesterol (p-interaction = 0.015). The T2D patients of CD36-G allele,
PPARG-G allele and NOS3-A allele tended to respond better to omega-3 fatty acids in improving lipid profiles.
The interaction results of the omega-3 fatty acid group were mainly attributed to the fish oil supplements.
Interpretation: This study suggests that T2D patients with different genotypes at CD36, NOS3 and PPARG respond
differentially to intervention of omega-3 supplements in blood lipid profiles.ensity lipop
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pen access article under1. Introduction
There has been a pronounced progress in thefield of nutrigenetics or
gene-diet interaction in the past decade, thanks to the great achieve-
ment in the identification of novel genetic variants related to diseases
in large-scale epidemiological studies and international consortium
[1–4]. The goal of gene-diet interaction is to tailor one's diet based on
his genetic background in contrast to the traditional “one-size-fits-all”
dietary recommendation. Although the concept of gene-diet interaction
is appealing, and progress within recent years is encouraging, lack ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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field and its translation into practice [1,4,5].
Omega-3 (or n-3) fatty acids, both marine (C20:5n-3, C22:5n-3,
C22:6n-3) and plant based (C18:3n-3), could improve blood lipid pro-
files and decrease risk of cardiovascular diseases [6–9]. Some interven-
tion studies suggest that effects of omega-3 fatty acids on blood lipids
could be modified by genetic variants and supports the existence of
gene-diet interaction for omega-3 fatty acids with regard to the lipid
outcomes [10–12]. In a systematic review, Corella et al. [13] suggested
that only three genes (CD36, NOS3 and PPARG) showed interactions
with omega-3 fatty acids to affect the levels of blood lipids in the inter-
vention studies, while no replication among trials has been reported so
far.
Therefore, the aim of the present studywas, to use a well-conducted
randomized controlled trial to replicate the previous findings from in-
tervention studies about the interaction of genetic variants (single-nu-
cleotide polymorphisms, SNP) at CD36, NOS3 and PPARG with omega-
3 fatty acid intervention for the blood lipids.
2. Materials and Methods
2.1. Study Population and Design
This study was based on a double-blind randomized controlled trial.
The trial was registered at ClinicalTrials.gov (No. NCT01857167), and
approved by the Ethics Committee of Colledge of BiosystemEngineering
and Food Science at Zhejiang University. All participants gave written
informed consent.
The inclusion and exclusion criteria, and the detailed procedures of
the trial has previous been reported [14]. Briefly, the inclusion criteria
were fasting blood glucoseN7.0 mmol/L or on use of diabetic medica-
tions, participants between 35 and 80 years for men or between
postmenopausal and 80 years for women; the exclusion criteria were
having familial hyperlipidemia or with blood triglycerides
N4.56 mmol/L, having a history of hepatic or kidney disease or any
type of cancer, or participation in another clinical trial within 30 days
prior to screening. The total sample size was calculated based on a
80% power with α= 0.05 to detect a difference in HOMA-IR by 0.63
(SD 1.1) between groups, considering a 20% drop out rate [14]. A total
of 185 patients with type 2 diabetes (T2D) were recruited in three re-
search centers at Wuhan, Changshan and Lanzhou, and randomized
into three groups: fish oil (n = 63), flaxseed oil (n = 61) and corn oil
group (n = 61). This was a double-blind randomized controlled trial,
and all the participants were randomly allocated to one of the three
treatments by computer-generated random sequence. Neither the re-
searchers randomizing the patients nor the patients knew the treat-
ments they were allocated before the randomization or during the
trial. Participants at each of the group took 4 capsules/day, correspond-
ing to 2 g/day of C20:5n-3 and C22:6n-3 in fish oil group, and 2.5 g/day
of C18:3n-3 in flaxseed oil group, with corn oil used as a control oil. The
trial lasted for 180 days. All patients were asked to maintain their usual
diet, lifestyle and medication, and avoid use of omega-3 fatty acid sup-
plements. Compliance of the participants to the interventionwas objec-
tively assessed by the measurement of erythrocyte fatty acids that
C20:5n-3 and C22:6n-3 was significantly increased in fish oil group
comparedwith corn oil group, and C18:3n-3was significantly increased
in flaxseed oil group comparedwith corn oil group [14]. Among the trial
participants, 150 patients provided DNA samples, of which 100 in
omega-3 supplement group (56 in fish oil group, 44 in flaxseed oil
group) and 50 in corn oil control group.
2.2. SNP Selection and Genotyping
SNPs rs1527483 at CD36, rs1799983 at NOS3, and rs1801282 at
PPARG were selected for genotyping based on the prior evidence [13].
Blood DNA was isolated by using the QIAamp DNA Blood Mini Kits(Qiagen, Valenica, CA, USA). The selected SNPs were genotyped using
the standard protocol recommended by the MassARRAY RS1000
(Sequenom, San Diego, CA, USA) manufacturer, and the data were ana-
lyzed by Typer 4.0 Software (Sequenom) [15],with an average genotyp-
ing success rate of 98%.
2.3.Measurement of Blood Lipids, Erythrocyte Phospholipid Fatty Acids, and
Other Parameters
Fasting blood samples were collected at baseline and the end of the
intervention. Serum high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and tri-
glycerides (TG) were measured by commercially available kits with
HITACHI 7020 chemistry analyser using enzyme-based colorimetric
test supplied by Diasys Diagnostic Systems (Shanghai) Co., Ltd. Erythro-
cyte phospholipid fatty acid compositionwasmeasured by gas chroma-
tography, as has been described previously [14]. Body weight and
height were measured by trained nurses at baseline and the end of
the intervention. Bodymass index (BMI)was calculated asweight in ki-
lograms divided by the square of the height in meters.
2.4. Statistical Analyses
All the statistical analyses were conducted using Stata (version 14;
StataCorp, College Station, TX, USA). All the lipid variables (HDL-C,
LDL-C, TC, TC/HDL-C, and TG) were checked for normal distribution
and were natural log-transformed if not normally distributed (for TG
only). Dominant models were used to assess the genetic effects and
the gene-diet interactions in the present study, as tomaximise the sam-
ple size in each genetic group. At baseline, the association between
blood lipids and genetic variants at CD36, NOS3 and PPARG was exam-
ined by linear regression models, adjusted for age, sex, study center
and BMI.
As the primary analysis, we examined the interaction of genetic var-
iants at CD36,NOS3 and PPARGwith omega-3 fatty acid supplements on
the change in blood lipids during the intervention based on the com-
plete case analysis. We used general linear model to test the
genotype-by-intervention interaction as independent predictors of
change in blood lipids, adjusting for age, sex, study center, BMI and
baseline value of the corresponding outcome trait. To increase the sam-
ple size and the power to detect the interaction, we combined fish oil
and flaxseed oi group into one omega-3 fatty acid supplement group,
as erythrocyte phospholipid C20:5n-3 and C22:6n-3 were increased in
both fish oil and flaxseed oil groups as reported previously [14]. Quanto
1.2.4 (University of Southern California) was used to estimate the de-
tectable effect size of genotype-by-diet interactions. For example, this
study had 80% power to detect significant gene-diet interaction effect
sizes (for rs1527483) of 0.27 mmol/L, 0.85 mmol/L, 0.97 mmol/L, 1.05,
and 0.9 mmol/L for change in HDL-C, LDL-C, TC, TC/HDL-C ratio and
TG under a dominant model, respectively.
In a secondary analysis, we examined the interaction between
change in erythrocyte phospholipid omega-3 fatty acids (sum of
C18:3n-3, C20:5n-3, C22:5n-3 and C22:6n-3, as a continuous variable)
and NOS3 genotypes for the change in lipid outcomes using the general
linearmodel, adjusting for age, sex, study center, BMI and baseline value
of the corresponding outcome trait. We conducted this secondary anal-
ysis because original paper reporting this gene-fatty acid interaction
was based on the interaction between change in plasma total omega-3
fatty acids and NOS3 variant on change in TG in an intervention study
[10].
If a significant interaction (p b 0.05) was detected, we conducted a
stratified analysis by the genotype groups and by intervention groups
using the general linearmodel. In addition,we also separately examined
the effects of different omega-3 fatty acid group (i.e.fish oil andflaxseed
oil group) on blood lipids by the tested genotypes.
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152 J.-S. Zheng et al. / EBioMedicine 31 (2018) 150–156In a post-hoc analysis, we generated a genetic score summing num-
ber of the omega-3 responsive allele across the 3 SNPs (rs1527483-G al-
lele, rs1799983-A allele and rs1801282-G allele). Carriers of these
alleles in the respective SNP or patients with a higher genetic score
showed a better response to omega-3 fatty acids in improving lipid pro-
files in the present study. We examined the interaction of this genetic
score (as a continuous variable) with omega-3 fatty acid intervention
on blood lipids using general linear model, adjusting for age, sex,
study center, BMI and baseline value of the corresponding outcome
trait. We subsequently conducted stratified analysis if a significant in-
teraction (p b 0.05) was observed.
3. Results
After the intervention, therewere 94 patients (53 infish oil and 41 in
flaxseed oil group) left in the omega-3 fatty acid supplement group, and
45 patients in corn oil control group. The minor allele frequency of
rs1527483 (A allele, CD36), rs1799983 (A allele, NOS3), and
rs1801282 (G allele, PPARG) was 0.223, 0.073 and 0.057, respectively,
and all SNPs were consistent with Hardy-Weinberg equilibrium (p N
0.05). The population characteristics by the genotypes and the interven-
tion group were presented at Table 1. At baseline, no difference in age,
BMI or lipid traits was observed among the different genotypes of the
three SNPs.
For CD36 SNP rs1527483,we found a significant interaction (p-inter-
action = 0.042) of the genotype with the intervention on serum TG
levels. Omega-3 supplements marginally decreased TG levels among
rs1527483-GG carriers (p = 0.067), but not among A allele carriers (p
= 0.19) (Table 2). When we separated fish oil and flaxseed oil group,
TG was decreased significantly among rs1527483-GG carriers after
fish oil supplements (p = 0.031), but not flaxseed oil supplements (p
= 0.39). No interaction was observed for other lipid outcomes.
We did not find any significant interaction between NOS3 SNP
rs1799983 and omega-3 fatty acid supplements on lipid traits
(Table 3). In our secondary analysis, we found that change in erythro-
cyte phospholipid omega-3 fatty acids had significant interaction with
rs1799983 on serum TG (p-interaction = 0.042), TC (p-interaction =
0.013) and TC/HDL-C (p-interaction = 0.015) (Fig. 2). In the low
omega-3 fatty acid change group (b1.38%, calculated based on the me-
dian level of the omega-3 fatty acid change), rs1799983 A allele carriers
had increased change in TG (p=0.035), TC (p=0.02) and TC/HDL-C (p
= 0.035) compared with CC carriers, while no difference was found in
the high omega-3 fatty acid change group (≥1.38%).
For PPARG SNP rs1801282, we observed that omega-3 supplements
interacted with the SNP to modulate LDL-C levels (p-interaction =
0.02). Stratified analysis suggested that GG/GC allele carriers had a sig-
nificantly higher increase in LDL-C compared with CC carriers in the
control group (p = 0.022), but no difference was observed in the total
omega-3 group, fish oil or flaxseed oil group (Table 4).
We observed a significant interaction between the genetic score and
omega-3 fatty acid supplements on TG levels (p-interaction = 0.04)
(Fig. 3), not for other lipids. Among the control group, serum TG levels
were significantly higher (p=0.008) in high genetic score group (com-
pared with low genetic score group), while no difference was observed
amongomega-3 supplement group. Omega-3 supplements significantly
decreased serum TG levels compared with control only among partici-
pants with a high genetic score (p = 0.026), and only fish oil (p =
0.009), not flaxseed oil, decreased TG in the subgroup analysis. (See
Fig. 3).
4. Discussion
In the present study, we successfully replicated the interaction of ge-
netic variants at CD36, NOS3 and PPARG with omega-3 fatty acids on
blood lipids. The T2D patients with CD36 major allele GG genotype,
but not A allele carriers, displayed a decreased TG concentration in
Table 2
Effects of omega-3 supplements on serum lipids by different genotypes at CD36 (rs1527483)a.
Total omega-3 supplements Fish oil supplements Flaxseed oil supplements Control
AA/AG (n = 41) GG (n = 55) AA/AG (n = 25) GG (n = 29) AA/AG (n = 16) GG (n = 26) AA/AG (n = 19) GG (n = 31)
HDL-C Baseline 1.15 (0.31) 1.17 (0.31) 1.15 (0.32) 1.14 (0.30) 1.16 (0.30) 1.21 (0.31) 1.24 (0.21) 1.14 (0.16)
After
intervention
1.20 (0.28) 1.25 (0.33) 1.24 (0.30) 1.23 (0.33) 1.14 (0.24) 1.27 (0.33) 1.37 (0.25) 1.18 (0.22)
Change 0.08 (0.18) 0.07 (0.23) 0.10 (0.21) 0.08 (0.24) 0.04 (0.11) 0.06 (0.22) 0.15 (0.14) 0.03 (0.18)
LDL-C Baseline 3.07 (0.78) 2.81 (0.87) 3.02 (0.78) 2.84 (0.85) 3.15 (0.81) 2.77 (0.91) 3.30 (1.02) 2.94 (0.75)
After
intervention
2.86 (0.71) 2.72 (0.81) 2.77 (0.69) 2.57 (0.89) 3.00 (0.74) 2.89 (0.69) 3.26 (0.97) 2.92 (0.90)
Change −0.23 (0.77) −0.10 (0.77) −0.3 (0.89) −0.3 (0.81) −0.12 (0.54) 0.12 (0.68) −0.13 (0.99) 0.01 (0.70)
TC Baseline 4.84 (0.86) 4.53 (0.96) 4.82 (0.88) 4.47 (0.93) 4.85 (0.86) 4.61 (1.00) 5.17 (1.08) 4.72 (0.99)
After
intervention
4.77 (0.86) 4.63 (0.99) 4.66 (0.80) 4.41 (1.05) 4.96 (0.95) 4.87 (0.88) 5.23 (1.08) 5.00 (1.22)
Change −0.05 (0.81) 0.06 (0.81) −0.19 (0.84) −0.12 (0.72) 0.18 (0.74) 0.26 (0.87) 0.22 (1.14) 0.29 (0.89)
TC/HDL-C Baseline 4.4 (1.03) 4.05 (1.12) 4.40 (0.98) 4.09 (1.13) 4.40 (1.13) 3.99 (1.14) 4.29 (1.18) 4.14 (0.79)
After
intervention
4.13 (1.02) 3.91 (1.14) 3.90 (0.86) 3.80 (1.16) 4.50 (1.17) 4.03 (1.14) 3.91 (0.85) 4.43 (1.87)
Change −0.34 (0.64) −0.16 (0.87) −0.56 (0.58) −0.34 (0.72) 0.02 (0.60) 0.03 (0.98) −0.42 (0.87) 0.31 (1.84)
TG (log-transformed) Baseline 0.44 (0.5) 0.40 (0.51) 0.45 (0.50) 0.39 (0.43) 0.42 (0.52) 0.43 (0.60) 0.56 (0.47) 0.48 (0.49)
After
intervention
0.39 (0.52) 0.28 (0.54) 0.27 (0.49) 0.20 (0.51) 0.59 (0.53) 0.36 (0.57) 0.37 (0.56) 0.54 (0.42)
Change⁎ −0.07 (0.34) −0.13 (0.42) −0.18 (0.35) −0.18 (0.39) 0.10 (0.25) −0.07 (0.45) −0.21 (0.37) 0.01 (0.33)
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
a Values are presented as mean (SD). Total omega-3 supplement group is a combination of fish oil and flaxseed oil groups.
⁎ Significant interaction (p-interaction= 0.042) between the CD36 genotypes and the total omega-3 supplements for the change in TGwas observed in the general linear model, after
adjustment for age, sex, study center, BMI and baseline value corresponding outcome. CD36 GG allele carriers showed a decrease in TG after intervention of omega-3 supplements (p =
0.067), especially in the fish oil group (p = 0.031) (compared with control group), but not in the A allele carriers.
153J.-S. Zheng et al. / EBioMedicine 31 (2018) 150–156response to the omega-3 intervention. Carriers of the PPARGminor G al-
lele, compared with those carrying CC genotype, showed increased
levels of LDL-C among control group, but not among the omega-3 inter-
vention group. We also replicated the interaction between erythrocyte
omega-3 fatty acid change and NOS3 variant on blood lipids that
rs1799983 minor A allele carriers responded better to high erythrocyte
omega-3 fatty acid in improving lipid profiles. A genetic score generated
based on the three SNPs demonstrated a combined effects of the three
SNPs for their interactions with omega-3 supplements on blood lipids.
The effect of the omega-3 supplement group was mainly attributed to
the fish oil supplements.
In a prior intervention study, 111 healthy Caucasianmen took 1.71 g
omega-3 fatty acids (C20:5n-3 + C22:6n-3) per day for 12 weeks [12],
significant decrease in TGonly occurred in participantswith theGG var-
iant of several CD36 SNPs, including rs1527483 [12]. CD36 is a gene
encoding CD36 protein (also known as fatty acid translocase [FAT]).Table 3
Effects of omega-3 supplements on serum lipids by different genotypes at NOS3 (rs1799983).a
Total omega-3 supplements Fish oil supp
AA/AC (n = 10) CC (n = 90) AA/AG (n =
HDL-C Baseline 1.13 (0.30) 1.17 (0.31) 1.38 (0.37)
After intervention 1.32 (0.29) 1.21 (0.31) 1.64 (0.33)
Change 0.19 (0.12) 0.06 (0.22) 0.26 (0.14)
LDL-C Baseline 3.02 (0.69) 2.94 (0.86) 3.24 (1.02)
After intervention 2.87 (0.75) 2.79 (0.78) 2.14 (0.31)
Change −0.15 (1.08) −0.17 (0.77) −1.10 (0.96
TC Baseline 4.72 (0.98) 4.71 (0.95) 5.38 (1.45)
After intervention 4.96 (1.13) 4.71 (0.95) 4.13 (0.41)
Change 0.24 (1.39) −0.02 (0.75) −1.25 (1.04
TC/HDL-C Baseline 4.30 (0.92) 4.24 (1.13) 3.93 (0.71)
After intervention 3.90 (1.12) 4.07 (1.14) 2.58 (0.48)
Change −0.40 (1.03) −0.21 (0.86) −1.36 (0.32
TG (log-transformed) Baseline 0.48 (0.46) 0.42 (0.51) 0.65 (0.41)
After intervention 0.40 (0.43) 0.33 (0.54) 0.19 (0.46)
Change −0.08 (0.31) −0.11 (0.39) −0.46 (0.15
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, tota
plements for the lipid traits was observed.
a Values are presented as mean (SD). Total omega-3 supplement group is a combination ofCD36 binds long-chain fatty acids and facilitates its transfer into cell,
playing an important role in fatty acidmetabolism [16–19]. A haplotype
containing the rs1527483 G allele was associated with increased levels
of TG, and was potentially associated with CD36 deficiency, which led
to the decrease in free fatty acid clearance and increase in the hepatic
free fatty acid update and production of TG [20]. It is also known that
omega-3 fatty acids, as PPAR agonist, could induce the CD36mRNA ex-
pression in different cell types [21,22], which may be potentially
through the regulation of the PPARG activity [23–25].
Therefore, the effects of omega-3 fatty acids on TG may partly in-
volve the modulation of CD36 activity, which renders the interaction
between CD36 variants and omega-3 intervention biologically plausible.
Based on the prior evidence [12] and results from the present study, it
could be hypothesized that TG-lowering effects of omega-3 supple-
ments may be more evident in the rs1527483 GG carriers, as a lower
CD36 activity in the GG group is more likely to be increased/restoredlements Flaxseed oil supplements Control
3) GG (n= 53) AA/AG (n= 7) GG (n= 37) AA/AC (n = 11) CC (n = 39)
1.13 (0.30) 1.03 (0.21) 1.21 (0.32) 1.17 (0.15) 1.18 (0.20)
1.21 (0.29) 1.19 (0.13) 1.22 (0.33) 1.22 (0.19) 1.26 (0.26)
0.08 (0.23) 0.16 (0.11) 0.03 (0.19) 0.09 (0.10) 0.07 (0.19)
2.95 (0.83) 2.93 (0.58) 2.94 (0.92) 2.84 (0.54) 3.14 (0.94)
2.71 (0.82) 3.19 (0.66) 2.91 (0.71) 2.92 (0.63) 3.08 (1.00)
) −0.27 (0.86) 0.26 (0.9) −0.02 (0.59) 0.19 (0.93) −0.11 (0.78)
4.66 (0.94) 4.44 (0.65) 4.77 (0.97) 4.66 (0.80) 4.95 (1.10)
4.60 (1.01) 5.32 (1.17) 4.86 (0.83) 4.54 (0.75) 5.23 (1.22)
) −0.11 (0.76) 0.88 (0.97) 0.13 (0.72) 0.06 (1.12) 0.32 (0.94)
4.30 (1.11) 4.46 (1.00) 4.15 (1.18) 4.02 (0.70) 4.25 (1.00)
3.95 (1.01) 4.46 (0.75) 4.26 (1.30) 3.75 (0.65) 4.37 (1.73)
) −0.42 (0.78) 0.00 (0.96) 0.09 (0.89) −0.24 (0.83) 0.13 (1.74)
0.42 (0.47) 0.41 (0.49) 0.43 (0.57) 0.45 (0.46) 0.53 (0.49)
0.26 (0.51) 0.49 (0.41) 0.43 (0.58) 0.47 (0.44) 0.47 (0.50)
) −0.16 (0.37) 0.08 (0.19) −0.03 (0.42) −0.02 (0.31) −0.08 (0.37)
l cholesterol; TG, triglycerides. No interaction betweenNOS3 genotypes and omega-3 sup-
fish oil and flaxseed oil groups.
Fig. 1. Flow diagram of the participants in the randomized controlled trial.
154 J.-S. Zheng et al. / EBioMedicine 31 (2018) 150–156by the omega-3 supplements compared to the other genotype group.
The functional SNPs in CD36 gene responsible for the observed interac-
tion are still not clear and warrant further investigation.
NOS3 gene encodes nitric oxide synthase 3, metabolizing L-arginine
to nitric oxide. Homozygotes (AA carriers) of the NOS3 SNP rs1799983
(also known as Glu298Asp) A minor allele have increased risk [26] of
cardiovascular diseases [10]. In a randomized trial among 450 individ-
uals with metabolic syndrome, carriers of the rs1799983 A allele
showed a greater response to increased plasma omega-3 fatty acid
levels in terms of reduction in TG levels [10]. In a cross-sectional analysis
of 248 participants, increased omega-3 fatty acid levels were positivelyTable 4
Effects of omega-3 supplements on serum lipids by different genotypes at PPARG (rs1801282)
Total omega-3 supplements Fish oil sup
GG/GC (n = 12) CC (n = 88) AA/AG (n =
HDL-C Baseline 1.20 (0.28) 1.16 (0.31) 1.16 (0.31)
After intervention 1.28 (0.25) 1.22 (0.31) 1.26 (0.25)
Change 0.08 (0.27) 0.07 (0.21) 0.10 (0.29)
LDL-C Baseline 3.35 (0.77) 2.90 (0.84) 3.19 (0.86)
After intervention 2.76 (0.68) 2.80 (0.79) 2.53 (0.63)
Change⁎ −0.54 (0.87) −0.12 (0.78) −0.65 (0.9
TC Baseline 5.23 (1.18) 4.64 (0.89) 4.92 (1.18)
After intervention 4.91 (1.03) 4.71 (0.96) 4.66 (1.15)
Change −0.43 (0.94) 0.07 (0.81) −0.43 (0.9
TC/HDL-C Baseline 4.49 (0.99) 4.21 (1.13) 4.38 (1.12)
After intervention 3.97 (1.06) 4.06 (1.14) 3.86 (1.15)
Change −0.55 (1.24) −0.19 (0.83) −0.63 (1.5
TG (log-transformed) Baseline 0.56 (0.54) 0.41 (0.49) 0.42 (0.49)
After intervention 0.42 (0.43) 0.32 (0.54) 0.32 (0.47)
Change −0.17 (0.41) −0.10 (0.38) −0.10 (0.3
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, to
a Values are presented as mean (SD). Total omega-3 supplement group is a combination of
⁎ Significant interaction (p-interaction = 0.02) between the PPARG genotypes and the omeg
adjustment for age, sex, study center, BMI and baseline value of corresponding outcome. PPAR
control group (p = 0.022), while no difference was observed among omega-3 groups.associated with endothelial function only in rs1799983 A allele carriers,
but not in the CC genotype carriers [27]. In another postprandial study
among 30 rs1799983A allele carriers and 29 rs1799983 C allele carriers,
only women with rs1799983 A allele were responsive to the beneficial
effect of omega-3 fatty acids on endothelial function [28].
The above literature together with the findings from the present
study suggest that rs1799983 minor A allele carriers might achieve
more benefits in terms of improved lipids and other cardiovascular pro-
files in response to a higher omega-3 fatty acid exposure, compared to
those with CC genotype. The above observed interaction is biological
plausible. The minor A allele was suggested to be associated with aa.
plements Flaxseed oil supplements Control
8) GG (n= 48) AA/AG (n = 4) GG (n= 40) GG/GC (n = 5) CC (n = 45)
1.14 (0.31) 1.26 (0.26) 1.17 (0.31) 1.22 (0.13) 1.18 (0.19)
1.23 (0.32) 1.34 (0.31) 1.20 (0.31) 1.31 (0.12) 1.25 (0.26)
0.09 (0.22) 0.03 (0.22) 0.05 (0.19) 0.07 (0.13) 0.08 (0.18)
−0.26 (0.85) 3.67 (0.51) 0.05 (0.66) 2.77 (0.58) 3.11 (0.89)
2.92 (0.83) 3.36 (0.39) 2.86 (0.87) 3.47 (0.54) 3.00 (0.96)
8) 2.71 (0.84) −0.23 (0.47) 2.92 (0.71) 0.80 (0.68) −0.13 (0.78)
4.66 (0.94) 5.85 (1.05) 4.60 (0.85) 4.60 (0.81) 4.92 (1.06)
4.55 (0.98) 5.49 (0.26) 4.90 (0.91) 5.27 (0.79) 5.07 (1.20)
9) −0.14 (0.79) −0.42 (1.02) 0.31 (0.78) 0.61 (0.80) 0.23 (0.99)
4.26 (1.10) 4.71 (0.77) 4.15 (1.17) 3.75 (0.28) 4.24 (0.98)
3.87 (1.03) 4.25 (0.96) 4.30 (1.24) 4.04 (0.49) 4.27 (1.66)
1) −0.45 (0.65) −0.35 (0.07) 0.11 (0.92) 0.29 (0.41) 0.03 (1.67)
0.43 (0.46) 0.85 (0.59) 0.39 (0.54) 0.49 (0.57) 0.51 (0.47)
0.24 (0.51) 0.67 (0.12) 0.42 (0.56) 0.81 (0.36) 0.44 (0.48)
7) −0.19 (0.37) −0.35 (0.55) 0.02 (0.37) 0.10 (0.20) −0.09 (0.37)
tal cholesterol; TG, triglycerides.
fish oil and flaxseed oil groups.
a-3 supplements for the change in LDL-C was observed in the general linear model, after
G G allele carriers had a higher increase in LDL-C level compared with CC carriers among
Fig. 2. Change in serum lipids stratified by change in erythrocyte phospholipid omega-3
fatty acids and NOS3 rs1799983 during the intervention. Values and error bars are
presented as mean and standard error. General linear model was used to estimate the
interaction between the change in erythrocyte phospholipid omega-3 fatty acids and
rs1799983 for the change in serum lipids, with significant interaction observed for TG
(p = 0.042), TC (p = 0.013) and TC/HDL-C (p = 0.015). *p b 0.05 indicated significant
difference in the lipid change between different genotype carriers among the low
omega-3 fatty acid change group (b1.38%, calculated based on the median level of the
omega-3 fatty acid change). HDL-C, high-density lipoprotein cholesterol; TC, total
cholesterol; TG, triglycerides.
Fig. 3. Change in serum triglycerides stratified by omega-3 fatty acid supplements and
genetic score of omega-3 responsive alleles. Values and error bars are presented as
mean and standard error. General linear model was used to estimate the interaction
between the total omega-3 fatty acid supplements and a genetic score of omega-3
responsive variants for the change in serum triglycerides (TG, p = 0.04). The genetic
score was a sum of the omega-3 responsive allele across the 3 SNPs (rs1527483-G allele,
rs1799983-A allele and rs1801282-G allele). Carriers of these alleles in the respective
variant showed a better response to omega-3 fatty acids in terms of improved lipid
profiles in the present study. High genetic score: score 2–4; low genetic score: score
0–1. *p b 0.05 indicated significant difference in the TG change between different
genetic score group among the control group and no significant difference was observed
in the other two groups.
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membrane fraction [29], while inhibition of NOS was found to be asso-
ciated with an increase in circulating TG and cholesterol [29]. Dietary
omega-3 fatty acid supplements could increase basal endothelial NO
production and also increase NOS3mRNA and protein levels [29].More-
over, omega-3 fatty acids were shown to regulate caveolar microenvi-
ronment, including the distribution and translocation of NOS in
caveolar [30,31]. Therefore, it is possible that omega-3 fatty acid supple-
ments compensate the disrupted NOS3 activity caused by the
rs1799983 minor A allele, whereas the homozygotes of the C major al-
lele might not get additional benefit given its normal NOS3 activity in
caveolar.
PPARG encodes peroxisome proliferator-activated receptor-gamma,
which is a transcription factor that regulates various genes involved inlipid storage, adipogenesis and insulin sensitization [32]. Animal
model showed that the rs1801282 variant, as an important modulator
inmetabolic control, was strongly subject to the influence of dietary fac-
tors or gene-diet interaction [33]. This conceptwas further confirmed in
human studies, where the interaction of the rs1801282 with dietary fat
intake has been reported in various populations [11,34–38]. In a con-
trolled trial among 150 individuals, participants were randomized to
consume fish oil supplement or placebo oil for 3 months. In that trial,
rs1801282 G allele carriers had a greater decrease in serum TG in re-
sponse to the omega-3 fatty acid supplements, compared with the CC
carriers [11]. SNP rs1801282 G allele carriers had higher levels of LDL-
C compared with CC carriers in a previous meta-analysis among Asian
populations [39]. We found consistent association in the control
group, but not in the omega-3 group. We hypothesized that the delete-
rious effect of rs1801282 G allele on LDL-C was attenuated by omega-3
fatty acids supplements.
There are several limitations in the present study. First, the sample
size of the present study is moderate, limiting the statistical power of
detecting a gene-diet interaction. Second, the combined intervention
group has a double sample size than the control group. However, the
impact of the difference in sample size on the interaction analysis
should be minimal, as we have also examined the interaction for fish
oil and flaxseed oil separately compared with control group and the re-
sults of fish oil is consistent with the combined intervention group
across different tested genes. Third, potential false positive results may
occur due to multiple testing, although we intends to replicate the
gene-diet interaction in previous reports and the tests are hypothesis
driven. We further demonstrate the existence of the interaction by
using a generic score of the 3 tested SNPs. Fourth, our study is based
on a Chinese population with T2D and the generalizability to other eth-
nicities or healthypopulationsmay be limited. Themajor strength of the
present study is that it is based on a well-conducted double-blind ran-
domized controlled trial, which lasts for 180 days with good participant
compliance as measured by erythrocyte fatty acid composition.
In conclusions, using a double-blind randomized controlled trial, we
replicated the interaction between omega-3 fatty acids and genetic var-
iants at CD36, NOS3 and PPARG on blood lipids reported in previous in-
tervention study. These replications suggest that the effects of omega-3
156 J.-S. Zheng et al. / EBioMedicine 31 (2018) 150–156fatty acids on blood lipids may vary by genetic variation at CD36, NOS3,
PPARG genes, and a personalized diet recommendation based on certain
genetic make-up to improve blood lipid profiles may work specifically
for omega-3 fatty acid intake. Nonetheless, this study is still quite pre-
liminary, and more trials with larger sample size are warrant.
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